Introduction
============

Cancer is a systems biology disease resulting from deregulation of cellular functions ([@b68-tog-2-2007-017]). Abnormalities leading to the transformation and malignant phenotype of cancer cells accumulate over time causing irregularities in signaling networks that control normal cell behavior. The features that distinguish malignant cancer cells from their non-transformed counterparts *in vivo* can be defined as: self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, and capability for tissue invasion and metastasis ([@b60-tog-2-2007-017]). The ability to recognize the molecular events that are involved in the acquisition and maintenance of these features of cancer cells should ultimately lead to better diagnostics and more effective therapies. Unfortunately our present knowledge of the biochemical events involved in malignant transformation, and of the biomarkers that could help to identify and characterize this process, is still too rudimentary. This is a consequence of three major factors: (i) an enormous molecular diversity of human cancers, (ii) limitations of the cancer model systems we use and (iii) the technical approaches we employ to study these model systems. The molecular diversity of human cancers reflects the heterogeneity and complexity of human tissues and organs. Even cancers of the same origin (for example colorectal cancers) can display significant variability with respect to molecular lesions associated with the transformed phenotype ([@b20-tog-2-2007-017]). This unfortunately is the biological reality that we must accept. It seems reasonable to assume that we need to better characterize and understand the biological diversity of human tumors at the molecular level in order to be able to design and develop more effective drugs and therapeutic strategies.The currently available cancer model systems can be classified into four major categories: (a) biopsies and surgically removed human tumors; (b) *in vitro* models based on primary cells or established cell lines; (c) human cancer cells grown *in vivo* as xenografts; (d) true animal models (i.e. animals, mainly rodents, in which tumor formation is triggered by genetic manipulations or treatment with carcinogens). Each of these model categories has advantages and disadvantages. Surgically removed tumor samples represent real human tumors, however they are more suitable for descriptive analysis rather than for mechanistic functional studies. *In vitro* models are relatively easy to investigate and well suited for high-throughput mechanistic approaches, but they are over-simplistic and prone to artifacts ([@b151-tog-2-2007-017]). Xenografts of human cancer cells provide a more complex *in vivo* micro-environment and display many features of real tumors but they are usually in non-physiological locations in immuno-compromised animals ([@b14-tog-2-2007-017]; [@b139-tog-2-2007-017]). True animal models provide full complexity and organ specificity of tumor development, however rodent cells are known to differ from human cells with respect to the events required for transformation ([@b59-tog-2-2007-017]; [@b124-tog-2-2007-017]). There are attempts to combine the advantages of different model systems (for example orthotopic implantation of human tumor fragments into the organs of nude mice) but they are technically challenging and their use is rather restricted ([@b18-tog-2-2007-017]). Considering the imperfections of the different categories of cancer model systems available, it is likely that comparative approaches combining the results obtained from different types of models may be most efficient in identifying the driving genetic lesions underlying cancer development and progression. Indeed, evidence supporting this prediction is starting to accumulate ([@b127-tog-2-2007-017]; [@b159-tog-2-2007-017]).Following the realization of the complexity of human carcinogenesis and the complications resulting from the limitations of the available models, it became apparent that only robust experimental approaches and improvements in cancer research technology may provide enough information to fully understand the biology of human cancers. Consequently in recent years this has resulted in the development and popularization of the "global" strategies including DNA microarrays and proteomics ([@b120-tog-2-2007-017]; [@b157-tog-2-2007-017]). Significant amounts of data from different cancer models have been obtained and the web-based bioinformatic resources aimed to facilitate discoveries from genome-wide and proteome-wide analyses are being developed ([@b126-tog-2-2007-017]; [@b126-tog-2-2007-017]; [@b175-tog-2-2007-017]; [@b76-tog-2-2007-017]; [@b103-tog-2-2007-017]). The advantages of these approaches over the methods used in the past are obvious and one can expect the "global analysis" trend to continue. In particular, these approaches will facilitate a deeper understanding of carcinogenesis as greater consideration will be given to quantitative and spatio-temporal data in the discovery of the control of complex signaling networks ([@b91-tog-2-2007-017]).

In the light of the accumulating genomic/proteomic information there is a pressing need for the development of robust function testing technologies to distinguish causal from bystander genetic abnormalities. These technologies should be used to generate more tightly controlled model systems that would allow mechanistic functional studies of particular genetic lesions in order to precisely define their biological consequences and importance in maintaining the transformed phenotype of cancer cells. Optimally such function-testing-oriented models should be reasonably easy to generate and allow real time, quantitative introduction of genetic lesions under investigation in a precisely controlled and reversible way. Tightly controlled mechanistic models are necessary to minimize the risks of artifacts resulting from the enormous adaptatory potential of cancer cells to enforced changes in their intracellular biochemical equilibrium ([@b78-tog-2-2007-017]).

It seems that inducible gene expression/suppression technologies developed by bioengineers over the last twenty years (for review see ([@b45-tog-2-2007-017]; [@b160-tog-2-2007-017]; [@b166-tog-2-2007-017])) can now fulfill the criteria of an optimal function-testing system ([@b137-tog-2-2007-017]). The gene expression/suppression systems controlled by tetracycline (tc) and its analogues (Tet-systems) represent the most mature technology of this kind ([@b17-tog-2-2007-017]). They can be precisely regulated *in vitro* and *in vivo* by a well characterized agent with favorable pharmacokinetic characteristics and facilitate elimination of non-specific compensatory mechanisms that often occur in models engineered for constitutive expression/suppression of the gene(s) of interest. We believe that they are now setting an improved technological standard in functional cancer research. The aim of this article is to provide an overview of the recent progress achieved in adopting Tet-systems to the purposes of functional oncogenomic research.

Tet-Systems: The Historical Perspective
=======================================

Tetracycline controlled gene expression/suppression systems in mammalian cells originate from Tet-operons in Gram-negative bacteria ([@b65-tog-2-2007-017]; [@b136-tog-2-2007-017]; [@b17-tog-2-2007-017]). In these bacteria the resistance to the antibiotics from the tetracycline family can be acquired by expression of energy-dependent membrane associated efflux proteins known as TetA. These proteins of approximately 43kDa contain 12 hydrophobic membrane-spanning regions and function as tetracycline/metal ion -- H^+^ anti-porters removing tetracycline/metal ion complexes (\[tc-Me\]^+^) from the cytoplasm to the periplasmatic space ([@b38-tog-2-2007-017]) ([Fig. 1](#f1-tog-2-2007-017){ref-type="fig"}). Several structurally related tetracycline/metal ion -- H^+^ antiporter proteins have been described to date (classes: A, B, C, D, E, G, H, I, J, Y, Z, 30, 31, 33, 38, 39, reviewed in ([@b129-tog-2-2007-017]; [@b28-tog-2-2007-017]; [@b130-tog-2-2007-017])). They are often associated with conjugative or mobilizable genetic elements (e.g. transposons) that facilitate their propagation among bacterial species. Although TetA proteins are protective against tetracyclines, they are poorly tolerated and have adverse effects on bacterial growth and viability when produced in excess ([@b115-tog-2-2007-017]). The delicate balance between the protective function of TetA against tetracyclines and its negative effects on cell growth is maintained by the precise control of TetA expression ([Fig. 1](#f1-tog-2-2007-017){ref-type="fig"}). Genetic organization and the mechanisms of regulation of the tetracycline resistance determinants have been best characterized for transposon Tn10 in *Escherichia coli* that contains genetic elements responsible for expression of TetA(B) protein (where (B) indicates the class of the determinant). It is believed that other classes of tet-resistance determinants have a similar mode of action ([@b65-tog-2-2007-017]).

The Tet-regulon on Tn10 (illustrated in [Fig. 1](#f1-tog-2-2007-017){ref-type="fig"}) consists of two genes localized next to each other and transcribed in opposite directions. One of the genes (tetA) encodes TetA antiporter whereas the other (tetR) encodes a regulatory protein known as Tet repressor (TetR). These genes are separated by a sequence of 81bp containing one promoter for tetA (tetP~A~) and two overlapping promoters for tetR (tetP~R1~ and tetP~R2~ respectively). The tetP~A~ and tetP~R~ promoters display opposite polarity and drive the expression of TetA and TetR respectively. The region containing tetP~A~ and tetP~R~ promoters also contains two very similar tet-operator (tetO) sequences called tetO~1~ and tetO~2~. Each of the operator sequences has a palindromic organization with a central base pair inserted on the symmetry axis and is recognized by TetR homodimers ((TetR)~2~) that are formed following TetR synthesis. The interaction of TetR homodimers with tetO~1~ and tetO~2~ sequences is mediated by the helix-turn-helix (HTH) motif on the TetR protein. Binding of (TetR)~2~ to the operator sequences interferes with the function of the promoters leading to the suppression of transcription. Thus, in the absence of tetracycline, synthesis of TetA and TetR is inhibited. When tetracyclines enter the cell they form an active tetracycline/metal ion complex \[tc-Me\]^+^ in the cytoplasm. The (TetR)~2~ homodimer can bind two \[tc-Me\]^+^ molecules. The affinity of TetR towards \[tc-Me\]^+^ complexes is very high with an association constant of ∼10^9^ M^−1^ ([@b66-tog-2-2007-017]). Following association with \[tc-Me\]^+^, the (TetR)~2~ undergoes conformational changes and its affinity to tetO is reduced by 6--10 orders of magnitude ([@b93-tog-2-2007-017]). This results in dissociation of the TetR homodimer from the tetO sequence and in transcription of the TetA and TetR genes ([@b65-tog-2-2007-017]; [@b136-tog-2-2007-017]).

The first evidence that the Tet repressor-operator system can be functional in eukaryotic cells was provided by Gatz and Quail ([@b47-tog-2-2007-017]). They demonstrated that in the protoplasts of *Nicotiana tabacum* the Tn10-encoded TetR protein (=TetR(B)) can regulate transcription from the cauliflower mosaic virus 35S promoter engineered to flank the "TATA" box with two tetO sequences ([@b47-tog-2-2007-017]). This observation provided foundations for the development of TetR regulated RNA polymerase II ([@b180-tog-2-2007-017]) and RNA polymerase III promoters ([@b117-tog-2-2007-017]) suitable for tetracycline regulated gene expression in mammalian cells. TetR regulated RNA polymerase II and III promoters can be used for tetracycline inducible expression of a protein of interest ([@b180-tog-2-2007-017]; [@b125-tog-2-2007-017]), antisense RNA ([@b117-tog-2-2007-017]), ribozymes ([@b22-tog-2-2007-017]), shRNAs ([@b34-tog-2-2007-017]; [@b106-tog-2-2007-017]; [@b162-tog-2-2007-017]) and micro RNAs ([@b148-tog-2-2007-017]). It is believed that in mammalian cells in the absence of tetracyclines, TetR reduces transcription from promoters engineered to include tetO sequences by steric interference with binding of RNA polymerase or other essential factors of the eukaryotic transcription machinery ([@b180-tog-2-2007-017]).

Recognition of the functionality of the Tet repressor-operator system in eukaryotic cells had also prompted construction of Tet repressor variants fused to the eukaryotic regulatory domains. This direction had been pioneered by Gossen and Bujard ([@b54-tog-2-2007-017]), and originally resulted in the generation of the tetracycline controlled transactivator tTA that is a fusion between TetR(B) protein and the C-terminal activating domain of virion protein 16 (VP16) of herpes simplex virus. In the absence of tetracycline, this transactivator enabled efficient expression of luciferase from the minimal promoter sequence of the human cytomegalovirus promoter IE preceded by seven tetO~2~ operators (tetO7-P~hCMVmin~). No luciferase activity was detected in the presence of tetracycline ([@b54-tog-2-2007-017]). The inducible systems based on the use of tTA (so called Tet-off systems) proved very useful in many applications (e.g. [@b42-tog-2-2007-017]; [@b116-tog-2-2007-017]; [@b48-tog-2-2007-017]; [@b67-tog-2-2007-017]), however they are compromised by the need for the sustained presence of tetracycline to maintain the un-induced state. This is very problematic, particularly in animal-based *in vivo* experiments. In addition, prolonged exposure to tetracyclines may have uncontrolled effects on the physiology of mammalian cells. Furthermore the kinetics of tetracycline removal required to trigger inducible gene expression are not always well controllable ([@b56-tog-2-2007-017]).

To overcome the disadvantages of the Tet-off systems, a random mutagenesis of the tetR(B) and screen for Tet repressors with reversed regulatory properties was performed in *Escherichia coli* ([@b56-tog-2-2007-017]). The screen resulted in the discovery of the first reverse Tet repressor (rTetR). The rTetR differs from the classical TetR(B) by four amino acid exchanges (Lys^71^ for Glu^71^, Asn^95^ for Asp^95^, Ser^101^ for Leu^101^, Asp^102^ for Gly^102^) and tetracyclines promote rather than abolish its binding to tet operators. Subsequent modification of the tTA construct by substitution of the TetR with rTetR resulted in the generation of the first reverse transcriptional transactivator (rtTA). The rtTA construct displays better sensitivity towards doxycycline (Dox) than towards tetracycline. Unlike tTA, rtTA induces gene expression in the presence rather than in the absence of tetracyclines ([@b56-tog-2-2007-017]). The inducible systems based on the use of the reverse transcriptional transactivators are known as Tet-on systems. Similarly to Tet-off systems, the first generation Tet-on systems based on the rtTA construct proved useful in multiple applications (e.g. ([@b27-tog-2-2007-017]; [@b135-tog-2-2007-017]; [@b164-tog-2-2007-017]; [@b58-tog-2-2007-017])). Unfortunately, their utility was restricted due to some negative properties of the rtTA construct that limit its application. These include (i) residual affinity of rtTA to tetO in the absence of Dox that results in background leakiness, (ii) relatively low stability of rtTA in mammalian cells that significantly complicates (or prevents) establishing of a functional Tet-on system in certain cell types, and (iii) the need for a relatively high Dox concentration required for full induction (1--2 μg/ml, this concentration cannot be readily achieved in some organs *in vivo*) ([@b161-tog-2-2007-017]).

The weaknesses of the first generation rtTA transactivator were overcome by the development of the second generation rtTAs. In *Saccharomyces cervisiae,* the original tTA construct was subjected to mutagenesis and functional screening for novel rtTA mutants with reduced basal activity and increased Dox sensitivity. Several new rtTAs were identified. The second generation reverse transcriptional transactivator with the most favorable properties, rtTA2S-M2, harbors five novel mutations in the TetR region (Gly^12^ for Ser^12^, Gly^19^ for Glu^19^, Pro^56^ for Ala^56^, Glu^148^ for Asp^148^, Arg^179^ for His^179^). It functions at 10-fold lower Dox concentration than rtTA, is more stable in eukaryotic cells and causes no background expression in the absence of Dox ([@b161-tog-2-2007-017]). Its coding sequence was optimized for use in human cells and the VP16 activation domain was substituted with three minimal activation domains (FFF motif) to reduce immunogeneity *in vivo* and to eliminate potential interactions with cellular transcription factors ([@b12-tog-2-2007-017]; [@b161-tog-2-2007-017]). The Tet-on systems utilizing second generation rtTA2S-M2 transactivator displayed superior properties in multiple applications *in vitro* and *in vivo* (see next section) ([@b79-tog-2-2007-017]; [@b88-tog-2-2007-017]; [@b80-tog-2-2007-017]; [@b121-tog-2-2007-017]).

In parallel to tetracycline regulated transcriptional transactivators utilizing eukaryotic transcriptional activator domains and forming the foundations of the Tet-off and Tet-on systems, tetracycline regulated transcriptional silencers (tTS) generated by fusing TetR to eukaryotic transcriptional silencing domains were also developed ([@b35-tog-2-2007-017]; [@b16-tog-2-2007-017]; [@b44-tog-2-2007-017]; [@b134-tog-2-2007-017]). In the absence of tetracycline these constructs exert silencing activity after binding to tetO sites placed in the proximity of the transcriptional initiation site of an eukaryotic promoter. Promoter activity is restored upon administration of tetracycline which prevents binding of tTS to the tetO sequences. Although some tTS' enabled tetracycline controlled gene expression from appropriately engineered promoters in mammalian cells ([@b35-tog-2-2007-017]), they did not became popular as independent regulatory systems. Instead they proved very useful in combination with the Tet-on systems, reducing residual leakiness in the absence of induction ([@b132-tog-2-2007-017]; [@b43-tog-2-2007-017]; [@b184-tog-2-2007-017]; [@b89-tog-2-2007-017]; [@b112-tog-2-2007-017]; [@b133-tog-2-2007-017]). The most commonly used construct of this type is the fusion of a mutant TetR and the KRAB-AB domain of the Kid-1 protein ([@b44-tog-2-2007-017]).

The comparison of TetR, tTA, rtTA and tTS---based systems is provided in [Fig. 2](#f2-tog-2-2007-017){ref-type="fig"}. It is worth mentioning that in addition to the well established developments listed above several new promising directions in the evolution of Tet-systems have been initiated. These include (but are not restricted to): (i) changes in DNA binding specificity of Tet-transregulators ([@b62-tog-2-2007-017]; [@b62-tog-2-2007-017]; [@b13-tog-2-2007-017]); (ii) Tet-transregulator setups allowing establishment of different levels of promoter activity ([@b79-tog-2-2007-017]; [@b83-tog-2-2007-017]), (iii) transactivator mutants with altered effector specificity to allow selective regulation of more than one gene ([@b84-tog-2-2007-017]; [@b85-tog-2-2007-017]); (iv) single-chain transregulators ([@b82-tog-2-2007-017]; [@b73-tog-2-2007-017]), and (v) tetracycline regulated aptamers allowing control at the translational level ([@b150-tog-2-2007-017]). The advances in the development of Tet-transregulators were complemented by significant progress in the generation of optimized responsive promoters and delivery systems (see next section) ([@b11-tog-2-2007-017]; [@b2-tog-2-2007-017]; [@b122-tog-2-2007-017]).

With over 600 papers based on the use of Tet-systems published last year (see [www.tetsystems.com](www.tetsystems.com) for a list of recent publications) the tetracycline regulated gene expression/suppression technology represents the most commonly used and the best characterized inducible platform for functional genomic research currently available. It has been successfully used in multiple model organisms ([@b17-tog-2-2007-017]) and is presently validated for the purposes of human gene therapy ([@b160-tog-2-2007-017]; [@b166-tog-2-2007-017]).

Tet-Systems in Functional Cancer Research
=========================================

The use of Tet-systems in functional cancer research has been increasing steadily over recent years, reflecting perhaps the improvements in Tet-technology and growing awareness of the necessity for stringent quantitative and spatio-temporal control of gene expression in mechanistic cancer model systems. In addition to their use in protein overexpression studies (we refer to them as "classical" Tet-systems) (e.g. [@b70-tog-2-2007-017]; [@b67-tog-2-2007-017]; [@b147-tog-2-2007-017]), Tet-systems have been successfully validated in loss-of-function experiments based on RNA interference mediated by regulated expression of short hairpin RNA (shRNA) ([@b34-tog-2-2007-017]; [@b106-tog-2-2007-017]; [@b162-tog-2-2007-017]; [@b177-tog-2-2007-017]; [@b100-tog-2-2007-017]; [@b104-tog-2-2007-017]; [@b4-tog-2-2007-017]; [@b179-tog-2-2007-017]) or shRNA imbedded in the microRNA context ([@b36-tog-2-2007-017]; [@b148-tog-2-2007-017]). Tet-vectors permitting both conditional gene expression and knockdown have been reported ([@b154-tog-2-2007-017]). Development of the multicistronic Tet-responsive cassettes that in addition to the gene(s) of interest enable expression of reporter genes like luciferase, green fluorescent protein (GFP), red fluorescent protein (RFP), PET-reporters or MRI-reporters brings the promise for efficient quantitative monitoring of inducible gene expression/suppression in tumor models *in vivo* ([@b77-tog-2-2007-017]; [@b153-tog-2-2007-017]; [@b30-tog-2-2007-017]; [@b36-tog-2-2007-017]; [@b155-tog-2-2007-017]; [@b172-tog-2-2007-017]). Tet-systems are advantageous over many other inducible technologies used in cancer research ([@b97-tog-2-2007-017]; [@b3-tog-2-2007-017]) also due to favorable properties of tetracyclines as inducing agents. Tetracyclines easily penetrate cellular membranes by diffusion ([@b7-tog-2-2007-017]), at low concentrations they have little or no pleiotropic effects in eukaryotic cells ([@b176-tog-2-2007-017]; [@b50-tog-2-2007-017]), and their biological effects *in vivo* are very well characterized after many years of use in the clinic ([@b143-tog-2-2007-017]).

The molecular lesions most frequently associated with cancer involve gene mutations and upregulation or downregulation of gene expression. As discussed above, the "classical" Tet-systems enable inducible gene expression ("upregulation") including expression of mutated genes, whereas Tet--dependent RNA interference enables regulated gene suppression ("downregulation"). Considering the high sequence specificity of the RNA interference process ([@b23-tog-2-2007-017]) and a possibility of introducing silent mutations into the coding sequences of exogenously engineered constructs, simultaneous knockdown of the endogenous gene and expression of its modified analogue in a Tet-controlled manner should also be possible. Thus Tet-technology seems to provide a range of tools sufficient to mimic (or reverse) the abnormalities commonly associated with transformed phenotype. In a drug discovery setting, Tet-based systems can be applied to up or down regulate wild type or mutated drug targets *in vitro* or *in vivo.* Such experiments provide opportunities to identify on or off target drug toxicities and potentially, could facilitate the search for biomarkers of drug responses ([@b51-tog-2-2007-017]).

To date the functional cancer studies based on the use of the Tet-technology have been successfully performed using diverse genes of interest in cells grown *in vitro* or *in vivo* (as xenografts) and in animal models. Considering the amount of publications and a broad range of applications described we are unable to provide the analysis of all the functional cancer research studies that employed Tet-systems, but a representative selection is presented in [Table 1](#t1-tog-2-2007-017){ref-type="table"}.

Development of a fully operational Tet-regulated cancer model system requires design and construction of fit-for-purpose Tet-genetic elements and their integration into the experimental system of choice. This must be followed by an in depth validation. Decision on the experimental system to be employed to address a defined biological question might sometimes be very difficult considering the advantages and disadvantages of different cancer model categories available (see introduction). Generally, cell based *in vitro* functional screens are better suited for initial high-throughput experiments whereas complex animal models might be more appropriate for advanced projects. However, the final choice of a model system to be employed depends on the nature of a problem to be investigated. Detailed discussion of the applicability of different approaches to human cancer modeling have been provided elsewhere ([@b163-tog-2-2007-017]; [@b151-tog-2-2007-017]; [@b14-tog-2-2007-017]; [@b139-tog-2-2007-017]) and is beyond the scope of this article. We shall concentrate on the design, construction and genetic integration of fit-for-purpose Tet-vectors and on the validation of the engineered tetracycline regulated models.

Inducible gene expression
-------------------------

Inducible expression of a heterologous protein in human cervical carcinoma HeLa cells using the Tet-off system represented the first "intersection" between cancer research and Tet-technology ([@b54-tog-2-2007-017]). Although many scientists recognized the advantages of this inducible approach over the standard over-expression techniques its implementation as a broadly used functional tool in cancer research was rather slow. This was a consequence of difficulties in setting up functional Tet models. Generation of such models used to be achieved in two consecutive steps. In the first step a transgenic line (cell or animal) expressing a Tet regulatory protein (tTA, rtTA or TetR) was established and the line with the most favorable properties was selected. In the second step, a responsive element encoding a gene of interest under control of a promoter engineered to include tetO sequences was introduced ([@b54-tog-2-2007-017]; [@b56-tog-2-2007-017]). Sometimes vectors encoding elements required for both steps were introduced simultaneously, although this usually resulted in models with less desirable properties (higher leakiness) ([@b144-tog-2-2007-017]). Unfortunately expression of tet-regulatory proteins in many cell lines (especially many types of human cancer cells) proved notoriously difficult and unstable ([@b53-tog-2-2007-017]; [@b114-tog-2-2007-017]). This very probably reflected characteristics of initially available Tet-regulatory proteins (low stability and potential cytotoxicity in mammalian cells ([@b144-tog-2-2007-017]; [@b46-tog-2-2007-017])) and high levels of epigenetic silencing of the expression vectors ([@b174-tog-2-2007-017]). Suboptimal vector delivery methods as well as inefficient selection and screening protocols may have also contributed to these initial difficulties. In addition to problems associated with stable expression of Tet-regulators, variability in the efficacy of tetracycline controlled gene expression between different cell types was reported ([@b1-tog-2-2007-017]; [@b71-tog-2-2007-017]). Furthermore mice based studies revealed that the functionality of Tet-systems in transgenic animals may be affected by the mouse strain used and the position of transgene integration ([@b144-tog-2-2007-017]; [@b131-tog-2-2007-017]). Despite all these "early" complications, several functional cell lines and transgenic mice were successfully established (reviewed in [@b145-tog-2-2007-017]; [@b137-tog-2-2007-017]; [@b31-tog-2-2007-017]; [@b185-tog-2-2007-017]). For example Ewald et al. using the Tet-off system demonstrated temporal requirement for viral oncogene expression in cellular transformation by SV40 large T antigen in submandibular gland ([@b39-tog-2-2007-017]) and Chin et al. using first generation Tet-on system showed essential role for oncogenic Ras in tumor maintenance in a mouse melanoma model ([@b27-tog-2-2007-017]).

Several discoveries that followed the initial "difficult" phase of implementating Tet-systems into functional cancer research significantly increased the success rate of generating cancer model systems employing Tet-regulated inducible gene expression. The most important of these discoveries include: (i) development and characterization of the second generation transcriptional transactivators, (ii) development of the "single vector" strategies for Tet-system delivery, (iii) development and characterization of virus based Tet-system delivery methods, (iv) realization that non-viral promoters may be more effective than viral promoters in driving prolonged expression of Tet- regulators in mammalian cells, and (v) use of improved selection protocols based on the IRES principle. Discovery of the second generation Tet-regulated transactivator rtTA2S-M2 by [@b161-tog-2-2007-017]). The superior properties of this construct have become obvious over the past five years and have enabled tightly controlled inducible gene expression in systems that resisted previous attempts based on older versions of Tet-regulators ([@b80-tog-2-2007-017]; [@b9-tog-2-2007-017]; [@b50-tog-2-2007-017]). Currently this transactivator represents the first choice of Tet-transactivator for tetracycline inducible gene expression approaches.The original two-step strategy of the generation of Tet systems may provide more flexibility in certain applications but is time consuming and labor intensive. The feasibility of delivering both a cassette expressing tTA transactivator and a cassette containing a reporter gene under control of a Tet regulated promoter in a single vector was demonstrated for the first time in tobacco plants ([@b170-tog-2-2007-017]). Placing both cassettes in opposing orientations was sufficient to avoid high levels of leaky expression ([@b170-tog-2-2007-017]). Following this study, single step Tet-vectors applicable for mammalian cells and animal models were developed ([@b141-tog-2-2007-017]). Those vectors were subsequently modified to include improved versions of Tet regulators and incorporated into highly efficient viral delivery systems (see below). It seems that the single-vector strategies might be more effective than two-step strategies in "omics" ---type functional cancer research.Many cell types cannot be efficiently transfected using standard methods like lipofection or electroporation. In addition certain cells, especially primary cells are very sensitive and cannot be subjected to a prolonged selection process. To facilitate the fast and reliable introduction of Tet-systems into such cells several groups described use of viral particles as Tet-system delivery vehicles. Viruses can be also used to efficiently transfect organs and tissues *in vivo*. So far efficient delivery of the Tet-systems components has been obtained using adenoviruses ([@b112-tog-2-2007-017]; [@b94-tog-2-2007-017]; [@b133-tog-2-2007-017]), adeno-associated viruses ([@b29-tog-2-2007-017]; [@b26-tog-2-2007-017]; [@b149-tog-2-2007-017]), retroviruses ([@b183-tog-2-2007-017]; [@b101-tog-2-2007-017]; [@b119-tog-2-2007-017]), parvo viruses ([@b108-tog-2-2007-017]; [@b118-tog-2-2007-017]), lentiviruses ([@b80-tog-2-2007-017]; [@b177-tog-2-2007-017]; [@b105-tog-2-2007-017]; [@b9-tog-2-2007-017]) and herpes viruses ([@b140-tog-2-2007-017]; [@b181-tog-2-2007-017]). Each type of the virus has slightly different properties with respect to integration status of delivered DNA, the spectrum of cells it can transfect, cellular toxicity and immunogeneity *in vivo*. Being able to integrate into the genomes of both dividing and non-dividing cells and having no cytotoxic effects, lentiviruses seem to provide the most sophisticated viral vectors for Tet-systems delivery in functional studies ([@b19-tog-2-2007-017]). In many studies, viral vectors were able to deliver fully operational Tet-systems to cells grown *in vitro* ([@b183-tog-2-2007-017]; [@b156-tog-2-2007-017]), to diverse organs of laboratory animals ([@b61-tog-2-2007-017]; [@b40-tog-2-2007-017]; [@b156-tog-2-2007-017]) and to tumor xenografts ([@b119-tog-2-2007-017]; [@b99-tog-2-2007-017]).Functionality of Tet-systems depends on continuous expression of the respective Tet-regulatory protein. Many early studies relied on the use of strong viral promoters to drive the expression of Tet regulatory proteins. More recent studies demonstrated that viral promoters are frequently silenced in human cancer cells and that use of strong non-viral promoters, for example elongation factor 1α (EF1α) or β-actin promoters, may significantly improve the efficiency of successfully generating functional Tet models ([@b53-tog-2-2007-017]; [@b21-tog-2-2007-017]; [@b172-tog-2-2007-017]). A similar observation was made in mouse mammary epithelial cell line HC11 ([@b75-tog-2-2007-017]). Considerable success was also achieved by using Tet-autoregulatory cassettes in which both the gene of interest and Tet-transactivator were placed under the control of a Tet-regulated promoter. Autoregulatory expression of rtTA allows extremely low levels of the transactivator and the transgene product in the absence of tetracyclines with enough rtTA molecules to induce expression upon addition of tetracy-clines ([@b105-tog-2-2007-017]).Stable cell lines selected to constitutively express Tet-regulatory protein may display its expression in only a fraction of the cell population. This heterogeneity of expression can be significantly reduced by direct selection for the presence of Tet-regulator. A few studies convincingly demonstrated that coupling the translation of a Tet-regulatory protein to a selectable reporter protein (e.g. an antibiotic resistance determinant or fluorescent marker) via an internal ribosome entry site (IRES) increases selection efficiency and enables generation of cells homogenously expressing Tet-regulator ([@b132-tog-2-2007-017]; [@b72-tog-2-2007-017]; [@b122-tog-2-2007-017]; [@b172-tog-2-2007-017]; [@b138-tog-2-2007-017]). A protocol for high throughput generation of human cancer Tet-on cell lines based on the use of IRES principle and expression of green fluorescent protein was recently published ([@b171-tog-2-2007-017]).

In addition to the developments listed above, the simultaneous use of rtTA2S-M2 transactivator and transcriptional silencer (tTS) or inclusion of insulator sequences in the Tet-responsive cassette might improve the characteristics and applicability of Tet-systems in functional studies even more by further reducing the risk of potential leaky expression ([@b87-tog-2-2007-017]; [@b122-tog-2-2007-017]; [@b121-tog-2-2007-017]; [@b133-tog-2-2007-017]). The technology that enables introduction of Tet-regulated target genes into a predetermined chromosomal loci in human cancer cells by recombinase mediated cassette exchange (RMCE) was also described recently and may provide another level of robustness in functional oncogenomics in the future ([@b178-tog-2-2007-017]). The RMCE methodology can be adapted for accelerated phenotype analysis in transgenic mice and in somatic cells ([@b158-tog-2-2007-017]). Precise spatio-temporal and cell-lineage-specific control of inducible gene expression in mice could be obtained by integration of Cre-mediated and tetracycline-dependent expression systems ([@b182-tog-2-2007-017]).

Inducible gene suppression
--------------------------

Tetracycline regulated suppression of gene function can be achieved by: (i) inducible over-expression of dominant negative mutants, (ii) conditional knock-out approaches, or (iii) inducible knockdown of gene expression at the RNA level. When over-expressed, dominant negative mutants are believed to interfere with physiological functions of endogenous proteins by competitive interaction with binding partners and downstream effectors. Tet-regulated expression of dominant negative mutants undergoes the principles described in the "inducible gene expression" section. This approach proved very informative in several cancer related studies (e.g. [@b111-tog-2-2007-017]; [@b52-tog-2-2007-017]) although interpretation of the results of the experiments employing dominant negative mutants may sometimes be complicated by the complex characteristics of their action ([@b142-tog-2-2007-017]).Tet-controlled conditional gene knockouts represent a powerful and informative approach to study gene function, however at present they are time, cost and labor intensive and not particularly well suited for high throughput functional analyses. They have been reviewed recently ([@b55-tog-2-2007-017]) and we will not discuss them here.Inhibiting endogenous proteins by knocking-down their mRNA levels represents the most robust way of functional gene suppression available at the moment. It has been successfully achieved by tetracycline inducible expression of antisense mRNAs ([@b102-tog-2-2007-017]; [@b152-tog-2-2007-017]) and ribozymes ([@b22-tog-2-2007-017]). However, the most effective way of Tet-regulated gene suppression relies on the RNA interference process with the use of short hairpin RNAs (shRNAs) ([@b5-tog-2-2007-017]; [@b37-tog-2-2007-017]). The first generation of vectors suitable for tetracycline-regulated targeting of diverse genes of interest by expression of shRNAs utilized unmodified TetR protein and either H1 ([@b162-tog-2-2007-017]), U6 ([@b34-tog-2-2007-017]; [@b106-tog-2-2007-017]) or 7SK ([@b34-tog-2-2007-017]) RNA polymerase III promoters engineered to include a single tetO site. These vectors proved readily applicable for both *in vitro* ([@b34-tog-2-2007-017]; [@b106-tog-2-2007-017]; [@b162-tog-2-2007-017]) and *in vivo* ([@b34-tog-2-2007-017]; [@b95-tog-2-2007-017]; [@b165-tog-2-2007-017]) studies. They have been also successfully incorporated into more efficient viral delivery vehicles ([@b177-tog-2-2007-017]; [@b69-tog-2-2007-017]; [@b86-tog-2-2007-017]; [@b4-tog-2-2007-017]). Even more tightly controlled inducible expression of shRNA could be achieved using U6 promoter modified to include two tetO sites ([@b100-tog-2-2007-017]; [@b98-tog-2-2007-017]). In some systems inducible expression of shRNA from Pol III promoters was achieved using tTS regulator ([@b25-tog-2-2007-017]; [@b154-tog-2-2007-017]). Tet-inducible RNA interference based on the use of RNA polymerase II promoter was subsequently described ([@b104-tog-2-2007-017]; [@b179-tog-2-2007-017]). The most promising recent development in the Tet-regulated RNA interference strategies is the discovery of a very high silencing potential of shRNAs embedded in the micro RNAs expressed from Pol II promoters ([@b36-tog-2-2007-017]; [@b148-tog-2-2007-017]). Regulation of Pol II promoters by components of Tet-systems can be much more sophisticated than regulation of Pol III promoters. Multicistronic co-transcription of reporter genes is also possible and might provide functional read-out and enable *in vivo* imaging ([@b36-tog-2-2007-017]; [@b148-tog-2-2007-017]). Tet-controlled expression of micro RNAs from Pol II promoters should enable tissue-specific, temporally regulated and reversible gene silencing *in vivo* ([@b33-tog-2-2007-017]). Despite being a relatively new development, Tet-regulated RNA interference has already proven its enormous applicability in cancer research ([@b25-tog-2-2007-017]; [@b107-tog-2-2007-017]). It seems to be particularly well suited for validating potential drug targets for cancer chemotherapy ([@b98-tog-2-2007-017]; [@b74-tog-2-2007-017]).

Validation of Tet models
------------------------

Due to the developments described above, generation of tightly regulated Tet cancer models is currently much less challenging than it was a few years ago. The constructed models, however, should still be carefully validated before they are used in functional studies. The validation process should comprise two steps: (i) comparison of the established Tet-model in the un-induced stage to its "parental" system from which it was generated; (ii) characterization of its functional properties. Considering the complex nature of the manipulations required during Tet-model construction, it is essential to ensure that the characteristics of the "parental" system have not been affected beyond an acceptable level. There are reports indicating that high levels of Tet-regulators might be cytotoxic *in vitro* ([@b46-tog-2-2007-017]) and trigger pathologies ([@b146-tog-2-2007-017]) and immune-responses ([@b90-tog-2-2007-017]; [@b96-tog-2-2007-017]) *in vivo*. In addition, integration of Tet-vectors into the genome of the host system may affect functions of endogenous genes, and the tight control of tetracycline-responsive expression may be compromised in some cells resulting in unacceptably high leakiness ([@b123-tog-2-2007-017]; [@b57-tog-2-2007-017]). This may also lead to physiological abnormalities. The use of tetracycline regulated models that do not preserve the characteristics of the parental system in the absence of induction may lead to artificial results and should be discouraged. Even for Tet-models that closely resemble their parental system when they are in the un-induced state, it is advisable to use at least two independently generated clones/lines to ensure the reliability of the results.Prior to more advanced mechanistic studies, the established Tet-systems should be characterized with respect to maximal induction levels and minimal concentration of tetracyclines required to achieve those levels, variation of inducibility within the system, and consistency of gene induction over time. This should confirm the model's reliability and help in early identification of potential complications ([@b10-tog-2-2007-017]). Published examples indicate that the levels and reversibility of transgene expression in Tet-models can be precisely controlled depending on the time of induction and concentration of tetracyclines used ([@b109-tog-2-2007-017]; [@b83-tog-2-2007-017]; [@b171-tog-2-2007-017]). In the case of *in vivo* experiments the kinetics of induction may also be associated with the route of drug administration ([@b109-tog-2-2007-017]). Thus a more extensive initial characterization of functional properties of the Tet-model, although time consuming, may significantly increase its utility and facilitate the design of subsequent experiments.

Concluding Remarks and Future Prospects
=======================================

DNA-microarray, proteomic and genome sequencing studies can define tumor specific mutations and genes the expression levels of which are upregulated or downregulated in cancer cells as compared to their non-transformed counterparts. The functional consequences and significance of these cancer-associated genetic lesions need to be understood. It seems that Tet-systems have evolved to the point where they can now satisfy the growing demands of functional oncogenomic research for quantitative, time-controlled and reversible function-testing strategies. This is particularly important regarding the increasing awareness that cancer is a very heterogeneous and dynamic disease, and in the context of the establishment of cancer systems biology as an independent branch of cancer science. There is accumulating evidence that tumor cells represent highly variable biochemical systems that undergo constant evolution and remain in a dynamic equilibrium with their continuously changing micro-environment. The consequences of a given genetic lesion depend not only on the cell type it affects but also on the metabolic status and precise localization of that cell in the tumor mass, as well as many other factors ([@b6-tog-2-2007-017]; [@b8-tog-2-2007-017]). Mutations that are essential for the maintenance of the transformed phenotype in early stages of tumorigenesis may play a less important role in later stages of tumor development ([@b49-tog-2-2007-017]), and immediate consequences of gene activation/inactivation may differ from longer-term consequences ([@b92-tog-2-2007-017]). Similarly the effects of high level activation of a given gene might be strikingly different from low-level activation ([@b173-tog-2-2007-017]). All these complications force the oncology community to look for more sophisticated experimental tools and place the inducible gene regulation technologies at the forefront of modern translational cancer research. Although standardized protocols for high-throughput functional-screens based on the use of tetracycline-regulated inducible gene expression/suppression still need to be developed, the progress achieved over the last few years in adopting this technology for the purposes of translational cancer research and human gene therapy has been very impressive. Without doubt the success achieved so far in applying Tet-systems to gain important insights into basic tumor biology and to validate potential drug targets in preclinical studies grants further development. Considering the fast expansion of systems biology approaches, one can expect that the future evolution of Tet-systems will place particular emphasis on real time, non-invasive visualization of the consequences of inducible gene expression/suppression in defined tissues and organs at a single cell level *in vivo*. Of course this should be accompanied by further improvements in quantitative control over the levels of gene expression/suppression. Furthermore it can be expected that alternative systems will be developed and optimized to additionally enhance the achievable degree of flexibility and control. Indeed promising results have been already reported using for example systems regulated by lactose, macrolide antibiotics and *Streptomyces*---derived quorum-sensing components. These systems, similarly to Tet-systems, combine a high degree of specificity with little pleiotropic side-effects ([@b32-tog-2-2007-017]; [@b110-tog-2-2007-017]; [@b167-tog-2-2007-017]; [@b169-tog-2-2007-017]; [@b64-tog-2-2007-017]; [@b24-tog-2-2007-017]; [@b168-tog-2-2007-017]). Combining tetracycline regulated systems with other inducible technologies may result in an even higher degree of control and provide invaluable tools necessary to unravel the intricate signalling networks involved in control of normal cell physiology and cell pathologies like cancer.

![Principles of the Tn10 encoded tetracycline resistance in *Escherichia coli*. The top part of the figure illustrates the function of TetA protein at the cytoplasmic membrane. The lower part illustrates organization and function of the Tet-regulon. The structures of tetracycline (tc) and tetracycline-metal ion complex (\[tc-Me\]^+^) are presented in the top right corner. See text for details.](tog-2-2007-017f1){#f1-tog-2-2007-017}

![Organization and function of Tet-systems utilizing different Tet-regulatory proteins. The schematics presented illustrate the functional principles only, the details of the structure of the genetic elements encoding Tet-regulatory proteins and of Tet-responsive cassettes vary between diverse published studies. See text for a detailed description.](tog-2-2007-017f2){#f2-tog-2-2007-017}

###### 

A selection of representative studies illustrating the diverse applications of Tet-technology in functional cancer research.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Model System**                                                 **Regulatory Element(s)**   **Description of the Study**                                                                                                                                                                                                                                                                                                                                                                        **Reference**
  ---------------------------------------------------------------- --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  Cells *in vitro* and subcutaneous xenografts                     tTA                         Inducible over-expression of membrane-type-1 matrix metalloproteinase (MT1-MMP) in non-malignant MDCK epithelial cells is by itself sufficient to drive formation of invasive tumors.                                                                                                                                                                                                               ([@b147-tog-2-2007-017])

  Cells *in vitro* and subcutaneous xenografts                     tTA                         Induction of fibroblast growth factor--2 (FGF-2) expression in human endometrial adenocarcinoma cells deeply affects the initial tumor growth and neovascularization but does not affect the progression of large tumors.                                                                                                                                                                           ([@b48-tog-2-2007-017])

  Cells *in vitro* and orthotopic xenografts                       tTA                         Demonstration that actinin-4 actively increases cell motility and promotes lymph node metastasis of colorectal cancer. The Tet-off system was used to express actinin-4 in DLD-1 colorectal cancer cells.                                                                                                                                                                                           ([@b67-tog-2-2007-017])

  Cells *in vitro* and subcutaneous xenografts                     rtTA                        This study shows that inducible expression of Bcl-Xs in human melanoma cells triggers apoptosis *in vitro* and delays growth of tumor xenografts *in vivo*.                                                                                                                                                                                                                                         ([@b70-tog-2-2007-017])

  Cells *in vitro* and orthotopic xenografts                       rtTA                        Using the Tet-on system in malignant astrocytoma cells, it was shown that p125FAK can promote tumor cell proliferation *in vivo* and that it was not due to less apoptosis.                                                                                                                                                                                                                         ([@b164-tog-2-2007-017])

  Cells *in vitro* and subcutaneous xenografts                     tTA\                        Antisense mRNA against mtCLIC/CLIC4 chloride channel protein expressed using Tet-off and Tet-on systems inhibited tumor growth and induced tumor apoptosis in human osteosarcoma cells.                                                                                                                                                                                                             ([@b152-tog-2-2007-017])
                                                                   rtTA                                                                                                                                                                                                                                                                                                                                                                                                                            

  Cells *in vitro*                                                 rtTA2S-M2\                  Inducible expression of GD3 ganglioside in glioblastoma cells was associated with apoptosis occurring via caspase-8 activation.                                                                                                                                                                                                                                                                     ([@b138-tog-2-2007-017])
                                                                   tTS                                                                                                                                                                                                                                                                                                                                                                                                                             

  Transgenic mice[\*](#tfn1-tog-2-2007-017){ref-type="table-fn"}   tTA                         Sustained expression of the MYC transgene in hematopoietic cells resulted in the formation of malignant T cell lymphomas and acute myeloid leukemias. The subsequent inactivation of the transgene caused regression of established tumors.                                                                                                                                                         ([@b42-tog-2-2007-017])

  Transgenic mice[\*](#tfn1-tog-2-2007-017){ref-type="table-fn"}   tTA                         Inducible expression of P210 BCR-ABL in stem and progenitor cells of murine bone marrow resulted in splenomegaly, myeloid bone marrow hyperplasia and extrameddulary myeloid cell infiltration of multiple organs. This recapitulates many characteristics of human chronic myeloid leukemia (CML).                                                                                                 ([@b81-tog-2-2007-017])

  Transgenic mice[\*](#tfn1-tog-2-2007-017){ref-type="table-fn"}   rtTA                        Demonstration that melanoma genesis and maintenance are strictly dependent upon expression of V12 H-Ras in a Dox-inducible V12 H-Ras mouse melanoma model null for the tumor suppressor INK4a.                                                                                                                                                                                                      ([@b27-tog-2-2007-017])

  Transgenic mice[\*](#tfn1-tog-2-2007-017){ref-type="table-fn"}   rtTA                        Inducible expression of activated receptor tyrosine kinase HER2/Neu in the mammary epithelium of transgenic mice resulted in development of multiple invasive mammary carcinomas that regressed following transgene deinduction demonstrating that Neu-initiated tumorigenesis is reversible. However the animals bearing regressed tumors ultimately developed Neu-independent recurrent tumors.   ([@b113-tog-2-2007-017])

  Cells *in vitro*                                                 TetR tTA                    Using breast cancer cell lines engineered to inducibly express or inducibly suppress expression of the Fra-1 gene the authors demonstrate a positive association between Fra-1 levels and cell proliferation, motility and invasiveness.                                                                                                                                                            ([@b15-tog-2-2007-017])

  Cells *in vitro* and orthotopic xenografts                       TetR                        Pol III promoter driven conditional expression of shRNA against PI-3 kinase subunits p110α and p110β showed a significant reduction in the formation of metastases following p110β but not p110α downregulation in prostate cancer cells.                                                                                                                                                           ([@b34-tog-2-2007-017])

  Subcutaneous xenografts                                          TetR                        Inducible downregulation of HIF-1α resulted in transcient tumor stasis and tumor regression. Inhibiting HIF-1α in early stage tumors was more efficacious than inhibiting HIF-1α in more established tumors.                                                                                                                                                                                        ([@b98-tog-2-2007-017])

  Subcutaneous xenografts                                          TetR                        Inducible silencing of the candidate tumor suppressor KILLER/DR5 in colon cancer cell lines resulted in accelerated growth of tumor xenografts and conferred resistance to the chemotherapeutic agent 5-fluorouracil                                                                                                                                                                                ([@b165-tog-2-2007-017])

  3D cell culture *in vitro* and orthotopic xenografts             TetR                        This study shows that a protein kinase C related molecule PKN3 is required for invasive prostate cell growth.                                                                                                                                                                                                                                                                                       ([@b95-tog-2-2007-017])

  Cells *in vitro* and subcutaneous xenografts                     tTA\                        Inducible RNA interference using microRNA-based shRNA expressed from the Pol II promoter. Tumors induced by Trp53 suppression and cooperating oncogenes regressed upon re-expression of Trp53.                                                                                                                                                                                                      ([@b36-tog-2-2007-017])
                                                                   rtTA                                                                                                                                                                                                                                                                                                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Several additional examples of the use of Tet-transgenic mice in cancer research can be found in the recent paper by ([@b41-tog-2-2007-017]).
